Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
2000 1
2003 1
2005 1
2008 1
2010 2
2011 1
2012 1
2014 3
2015 4
2016 7
2017 5
2018 4
2019 6
2020 4
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Functional genomic landscape of acute myeloid leukaemia.
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Tyner JW, et al. Among authors: traer e. Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17. Nature. 2018. PMID: 30333627 Free PMC article.
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.
Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, Fillmore TL, Tsai CF, Schepmoes AA, Shi T, Arshad OA, McDermott JE, Babur O, Watanabe-Smith K, Demir E, D'Alessandro A, Liu T, Tognon CE, Tyner JW, McWeeney SK, Rodland KD, Druker BJ, Traer E. Joshi SK, et al. Among authors: traer e. Cancer Cell. 2021 Jul 12;39(7):999-1014.e8. doi: 10.1016/j.ccell.2021.06.003. Epub 2021 Jun 24. Cancer Cell. 2021. PMID: 34171263
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. DiNardo CD, et al. Among authors: traer e. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. N Engl J Med. 2018. PMID: 29860938 Free article. Clinical Trial.
IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H, Fletcher L, Traer E. McMurry H, et al. Among authors: traer e. Curr Hematol Malig Rep. 2021 Apr;16(2):207-217. doi: 10.1007/s11899-021-00619-3. Epub 2021 Apr 30. Curr Hematol Malig Rep. 2021. PMID: 33939107 Review.
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Burd A, et al. Among authors: traer e. Nat Med. 2020 Dec;26(12):1852-1858. doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26. Nat Med. 2020. PMID: 33106665 Free PMC article. Clinical Trial.
Reducing acetyl-CoA enhances BET inhibition.
Traer E. Traer E. Blood. 2019 Dec 12;134(24):2122-2123. doi: 10.1182/blood.2019003653. Blood. 2019. PMID: 31830279 Free article. No abstract available.
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.
Joshi SK, Keck JM, Eide CA, Bottomly D, Traer E, Tyner JW, McWeeney SK, Tognon CE, Druker BJ. Joshi SK, et al. Among authors: traer e. Leukemia. 2020 Oct;34(10):2798-2804. doi: 10.1038/s41375-020-0844-7. Epub 2020 May 4. Leukemia. 2020. PMID: 32366937 Free PMC article. No abstract available.
42 results